Clinical trials: Atopic Dermatitis, open to volunteers
Atopic Dermatitis
Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis
This is a bridging study only for Chinese subjects. The goal of this clinical trial is to learn if drug Nemolizumab works to treat moderate to severe AD in over 12 years old male and female.
- Trial name
- NCT07762833
- Testing
- Nemolizumab 30 mg
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Galderma R&D
Allergy, Sinus Disorders, Atopic Diseases, Asthma, Allergic Rhinitis, Atopic Dermatitis, EoE, Drug a
A Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-Up
Background: Allergic or sinus diseases can affect the skin, sinuses, airways, and other parts of the body. Examples include pollen and environmental allergies, food allergies, asthma, and eczema.
- Trial name
- NCT06732414
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Atopic Dermatitis (AD)
A Phase III Study of GS101 Injection to Dupixent®
This is a a multicenter, randomized, double-blinded, parallel, positive-controlled, Phase III comparative study to evaluate GS101 Injection versus Dupixent® in participants with moderate-to-severe atopic dermatitis.
- Trial name
- NCT07386743
- Testing
- GS101 injection, DUPIXENT®
- Where
- China
- Volunteers
- 572 people
- Sponsor
- Jiangsu Genscend Biopharmaceutical Co., Ltd
Atopic Dermatitis
A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic Dermatitis
This study is expected to include approximately 520 patients with moderate to severe AD, and they will be randomly assigned to the treatment group (IBI3027) and the control group (Dupilumab Injection ) in a 1:1 ratio.
- Trial name
- NCT07754786
- Testing
- Dupilumab Injection, IBI3027
- Where
- China
- Volunteers
- 520 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Atopic Dermatitis
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema
The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body when used together with medicated creams or ointments in adults and adolescents with moderate to severe atopic…
- Trial name
- NCT07765888
- Testing
- Tilrekimig
- Where
- 21 sites in United States, Japan
- Volunteers
- 375 people
- Sponsor
- Pfizer
Atopic Dermatitis
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
The main aim of the study is to evaluate the efficacy and safety of lebrikizumab treatment for up to 32 weeks in participants with moderate-to-severe face and neck atopic dermatitis (FNAD) who also have moderate-to-severe AD…
- Trial name
- ADface (NCT07873801)
- Testing
- Lebrikizumab
- Volunteers
- 230 people
- Sponsor
- Almirall, S.A.
Dermatitis, Atopic
Evaluation of 611 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD)
This study is a 2-part (parts A and B) study.The primary objective of the study is to evaluate the efficacy of 611 in Chinese Children with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT07767253
- Testing
- 611
- Where
- 5 sites in China
- Volunteers
- 246 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Atopic Dermatitis
Phase 1 Study of QX-4533 in Healthy Volunteers and Patients With Moderate-to-Severe Atopic Dermatitis
The goal of this clinical trial is to evaluate the safety and tolerability of QX-453, an investigational treatment, in healthy Chinese volunteers and patients with moderate-to-severe atopic dermatitis.
- Trial name
- NCT07800104
- Testing
- QX4533
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- QuantX Biosciences, Inc.
Atopic Dermatitis
AD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of Patient-Centered Outcomes
The goal of this Phase 4 clinical study is to learn how Ebglyss (lebrikizumab) works and how it is dosed in everyday dermatology care for adults and adolescents (age 12 and older) with moderate-to-severe atopic dermatitis…
- Trial name
- AD-TEMPO (NCT07856134)
- Testing
- Lebrikizumab-lbkz
- Where
- 10 sites in United States
- Volunteers
- 250 people
- Sponsor
- Forefront Dermatology S.C
Atopic Dermatitis
Retention of Vernix Caseosa in Newborns for Primary Prevention of Atopic Dermatitis
Atopic dermatitis (AD), also known as eczema, is a common chronic inflammatory skin disease that usually begins in infancy and causes significant itching, discomfort, and sleep disturbance.
- Trial name
- PROTEGO (NCT07333378)
- Testing
- Retention of Vernix Caseosa After Birth, Removal of Vernix Caseosa After Birth
- Where
- 2 sites in Chile
- Volunteers
- 1,383 people, healthy volunteers welcome
- Sponsor
- Pontificia Universidad Catolica de Chile
Atopic Dermatitis, Healthy Participants
A Study of BYN-001 in Healthy Adults and in Adults With Moderate to Severe Atopic Dermatitis
This first-in-human study evaluates BYN-001, a humanized IgG1 monoclonal antibody targeting interleukin-25 (IL-25), a cytokine implicated in atopic dermatitis.
- Trial name
- BYN-001-101 (NCT07746817)
- Testing
- BYN-001
- Where
- Australia
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Bionyra Pharma
Atopic Dermatitis (AD)
A Study of JYP0066 Cream in Mild-to-Moderate Atopic Dermatitis
This is a Phase 2 research study testing an investigational topical cream called JYP0066 for the treatment of mild-to-moderate atopic dermatitis (eczema) in teenagers (12-17 years old) and adults.
- Trial name
- NCT07843290
- Testing
- JYP0066 4% topical cream, 3% JYP0066 topical cream, 2% JYP0066 topical cream
- Volunteers
- 160 people
- Sponsor
- Guangzhou JOYO Pharma Co., Ltd
Atopic Dermatitis
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
This is a Phase 1, randomized, blinded, placebo controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis…
- Trial name
- NCT06808477
- Testing
- BBT001
- Where
- 14 sites in United States, Australia and 2 more
- Volunteers
- 237 people, healthy volunteers welcome
- Sponsor
- Bambusa Therapeutics
Atopic Dermatitis
Abrocitinib Dose Tapering in Patients With Atopic Dermatitis
This prospective, multicenter study aims to evaluate whether patients with moderate-to-severe atopic dermatitis who achieve optimal disease control during treatment with abrocitinib 200 mg once daily can maintain disease control…
- Trial name
- MODA-AD (NCT07848074)
- Testing
- Abrocitinib
- Volunteers
- 100 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Atopic Dermatitis
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT06947993
- Testing
- GHZ339
- Where
- 105 sites in United States, Argentina and 15 more
- Volunteers
- 224 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis (AD)
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
The goal of this clinical trial is to learn about the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis.
- Trial name
- NCT07298395
- Testing
- ENV-294
- Where
- 32 sites in United States
- Volunteers
- 105 people
- Sponsor
- Enveda Therapeutics
Atopic Dermatitis
Oral Melatonin as Adjunctive Therapy in Adults With Atopic Dermatitis
Atopic dermatitis is a chronic inflammatory skin disease that is commonly associated with itching, sleep disturbance, and impaired quality of life.
- Trial name
- MEL-AD (NCT07842900)
- Testing
- Melatonin, Standard Treatment for Atopic Dermatitis
- Volunteers
- 130 people
- Sponsor
- Can Tho University of Medicine and Pharmacy
Atopic Dermatitis
Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age
This clinical study is designed to test how well a medicine called abrocitinib works and how safe it is for young children (ages 2 to under 6) who have moderate-to-severe eczema (also known as atopic dermatitis).Eczema is a skin…
- Trial name
- NCT07823595
- Testing
- Abrocitinib
- Volunteers
- 90 people
- Sponsor
- Pfizer
Atopic Dermatitis (AD), Scabies
Secondary Bacterial Infections and Nasal Colonization in Scabies and Atopic Dermatitis
This prospective observational study will evaluate the microbiological profile of secondary bacterial infection and nasal colonization in participants with scabies or atopic dermatitis.
- Conditions
- Atopic Dermatitis (AD), Scabies, Impetigo
- Trial name
- NCT07813611
- Where
- Turkey (Türkiye)
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Istanbul Medeniyet University
Eczema, Atopic Dermatitis
The Impact of Dietary Salt on the Severity of Eczema
The goal of this clinical trial is to evaluate the feasibility of low-sodium diet to improve eczema severity. The main questions it aims to answer are: Does a low-sodium diet improve eczema severity? How does a low-sodium diet…
- Trial name
- iDOSE (NCT07447063)
- Testing
- Sodium chloride tablets
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco